{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:28:24Z","timestamp":1789716504707,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1124\/dmd.114.059154","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T14:31:22Z","timestamp":1404225082000},"page":"1401-1406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell\u2013Derived Hepatocytes"],"prefix":"10.1016","volume":"42","author":[{"given":"Gustav","family":"Holmgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Sabirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sartipy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Synnergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bj\u00f6rquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy B.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Edsbagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.059154_bib1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.2012.685159","article-title":"The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human","volume":"8","author":"Andersson","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.114.059154_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059154_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1124\/dmd.109.030197","article-title":"Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells","volume":"38","author":"Anth\u00e9rieu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059154_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.taap.2013.11.022","article-title":"Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans","volume":"275","author":"Atienzar","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.114.059154_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0168-8278(97)80494-1","article-title":"Hepatotoxicity in drug development: detection, significance and solutions","volume":"26","author":"Ballet","year":"1997","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.114.059154_bib6","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00003088-200342080-00005","article-title":"Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions","volume":"42","author":"Bredberg","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.059154_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jbiotec.2009.11.007","article-title":"Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage","volume":"145","author":"Brol\u00e9n","year":"2010","journal-title":"J Biotechnol"},{"key":"10.1124\/dmd.114.059154_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.taap.2013.10.032","article-title":"Hepatocyte-based in vitro model for assessment of drug-induced cholestasis","volume":"274","author":"Chatterjee","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.114.059154_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/dmd.31.5.645","article-title":"Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug","volume":"31","author":"Clement","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059154_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/BF02931073","article-title":"Aflatoxins: detection, toxicity, and biosynthesis","volume":"12","author":"Do","year":"2007","journal-title":"Biotechnol Bioprocess Eng"},{"key":"10.1124\/dmd.114.059154_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.18433\/J3SG66","article-title":"The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole","volume":"11","author":"Elsherbiny","year":"2008","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/dmd.114.059154_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.tiv.2008.11.012","article-title":"Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach","volume":"23","author":"Gerets","year":"2009","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/dmd.114.059154_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol Toxicol"},{"key":"10.1124\/dmd.114.059154_bib14","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.114.059154_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.059154_bib16","first-page":"557","article-title":"Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer","volume":"104","author":"Guengerich","year":"1996","journal-title":"Environ Health Perspect"},{"key":"10.1124\/dmd.114.059154_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-60761-688-7_1","article-title":"General review on in vitro hepatocyte models and their applications","volume":"640","author":"Guguen-Guillouzo","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.114.059154_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/17425255.4.10.1279","article-title":"Evolving concepts in liver tissue modeling and implications for in vitro toxicology","volume":"4","author":"Guillouzo","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.114.059154_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nprot.2012.153","article-title":"Production of hepatocyte-like cells from human pluripotent stem cells","volume":"8","author":"Hannan","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1124\/dmd.114.059154_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfm021","article-title":"Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?","volume":"97","author":"Jaeschke","year":"2007","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.114.059154_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/dmd.107.017418","article-title":"HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.059154_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/tx000180q","article-title":"Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo: evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission","volume":"14","author":"Kassahun","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.114.059154_bib23","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/hep.20634","article-title":"Mechanisms of benzarone and benzbromarone-induced hepatic toxicity","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Hepatology"},{"key":"10.1124\/dmd.114.059154_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.tiv.2007.11.014","article-title":"Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran","volume":"22","author":"Kenne","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/dmd.114.059154_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/toxsci\/kfs326","article-title":"Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans","volume":"132","author":"Khetani","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.114.059154_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.114.059154_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"10.1124\/dmd.114.059154_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1124\/dmd.114.059154_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.drudis.2013.11.014","article-title":"Reducing attrition in drug development: smart loading preclinical safety assessment","volume":"19","author":"Roberts","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.114.059154_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0006-291X(87)90628-0","article-title":"Drug metabolism by the human hepatoma cell, Hep G2","volume":"143","author":"Sassa","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.114.059154_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.23354","article-title":"Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells","volume":"51","author":"Si-Tayeb","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/dmd.114.059154_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5966\/sctm.2013-0146","article-title":"Accurate prediction of drug-induced liver injury using stem cell-derived populations","volume":"3","author":"Szkolnicka","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1124\/dmd.114.059154_bib33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1124\/dmd.114.059154_bib34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"10.1124\/dmd.114.059154_bib35","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.23506","article-title":"Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development","volume":"51","author":"Touboul","year":"2010","journal-title":"Hepatology"},{"key":"10.1124\/dmd.114.059154_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bcp.2013.06.029","article-title":"Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells","volume":"86","author":"Ulvestad","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.059154_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbi.2004.09.011","article-title":"Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential","volume":"150","author":"Xu","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.114.059154_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/toxsci\/kfr225","article-title":"Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity.","volume":"124","author":"Yildirimman","year":"2011","journal-title":"Toxicol Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624099872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624099872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.059154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:17:00Z","timestamp":1739906220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624099872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0090955624099872"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.059154","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell\u2013Derived Hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.059154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}